Newsroom

Recent News Releases

December 8, 2022 12/8/2022

Takeda’s QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated]) Approved for Use in European Union

November 22, 2022 11/22/2022

Takeda’s Biologics License Application (BLA) for Dengue Vaccine Candidate (TAK-003) Granted Priority Review by U.S. Food and Drug Administration

November 17, 2022 11/17/2022

Phase 3 Trial of ICLUSIG^® (ponatinib) Met Primary Endpoint in Newly-Diagnosed Ph+ ALL, a Setting with No Targeted Treatments Approved in the US

November 11, 2022 11/11/2022

European Commission (EC) Approves LIVTENCITY^TM▼ (maribavir) for the Treatment of Adults With Post-transplant Cytomegalovirus (CMV) Infection And/or Disease That Are Refractory (With or Without Resistance) to One or More Prior Therapies

October 27, 2022 10/27/2022

Takeda Delivers Strong FY2022 H1 Results and Raises Full-Year Forecast

SEE ALL NEWS AND RELEASES >

・For Shire news releases, click here

Featured Topics

Luck is not a strategy: The world needs to start preparing now for the next pandemic

Learn more

The COVID-19 Mental Burden on Working Mothers

Learn more

Takeda Neuroscience at the Annual Meeting of the American Academy of Neurology (AAN) 2021

Learn more

Takeda Breaks Ground on Commercial Cell Therapy Manufacturing Facility in Lexington, Massachusetts

Learn more

Spotlight Malawi: Many Paths Towards Universal Health Coverage and a Strong Health Workforce

Learn more

SEE ALL FEATURED TOPICS ARTICLES >

In the News

With this new original series featured in Asahi Shimbun Globe, President & CEO Christophe Weber gives his unique perspective on what he has learned from his upbringing in France and his international career.

LEARN MORE

Executive Leadership

Meet our Executive Leadership Team led by our President and CEO, Christophe Weber

LEARN MORE

For media inquiries or reporter requests for more information, contact our Corporate Communications via Media_Relations@takeda.com. If you generally would like to contact us, please visit Contact Us.